JP2013504576A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013504576A5 JP2013504576A5 JP2012528855A JP2012528855A JP2013504576A5 JP 2013504576 A5 JP2013504576 A5 JP 2013504576A5 JP 2012528855 A JP2012528855 A JP 2012528855A JP 2012528855 A JP2012528855 A JP 2012528855A JP 2013504576 A5 JP2013504576 A5 JP 2013504576A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- pharmaceutically acceptable
- compound
- acceptable salt
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 59
- 125000000217 alkyl group Chemical group 0.000 claims description 38
- -1 TLR-7 agonists Substances 0.000 claims description 36
- 125000003118 aryl group Chemical group 0.000 claims description 30
- 125000000623 heterocyclic group Chemical group 0.000 claims description 30
- 150000003839 salts Chemical class 0.000 claims description 29
- 239000003112 inhibitor Substances 0.000 claims description 24
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims description 21
- 125000002947 alkylene group Chemical group 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 239000005557 antagonist Substances 0.000 claims description 8
- 108700008776 hepatitis C virus NS-5 Proteins 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 239000002777 nucleoside Substances 0.000 claims description 8
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 230000009385 viral infection Effects 0.000 claims description 5
- KJTLQQUUPVSXIM-ZCFIWIBFSA-M (R)-mevalonate Chemical compound OCC[C@](O)(C)CC([O-])=O KJTLQQUUPVSXIM-ZCFIWIBFSA-M 0.000 claims description 4
- 101001023866 Arabidopsis thaliana Mannosyl-oligosaccharide glucosidase GCS1 Proteins 0.000 claims description 4
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 claims description 4
- FWKQNCXZGNBPFD-UHFFFAOYSA-N Guaiazulene Chemical compound CC(C)C1=CC=C(C)C2=CC=C(C)C2=C1 FWKQNCXZGNBPFD-UHFFFAOYSA-N 0.000 claims description 4
- 229940124771 HCV-NS3 protease inhibitor Drugs 0.000 claims description 4
- 102000014150 Interferons Human genes 0.000 claims description 4
- 108010050904 Interferons Proteins 0.000 claims description 4
- 101800001014 Non-structural protein 5A Proteins 0.000 claims description 4
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 4
- 208000036142 Viral infection Diseases 0.000 claims description 4
- 230000003510 anti-fibrotic effect Effects 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 4
- 239000000134 cyclophilin inhibitor Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000002308 endothelin receptor antagonist Substances 0.000 claims description 4
- 239000003623 enhancer Substances 0.000 claims description 4
- 229940079322 interferon Drugs 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 230000036454 renin-angiotensin system Effects 0.000 claims description 4
- 229960000329 ribavirin Drugs 0.000 claims description 4
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 claims description 4
- 241000710781 Flaviviridae Species 0.000 claims description 3
- 125000004419 alkynylene group Chemical group 0.000 claims description 3
- 125000000732 arylene group Chemical group 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 241000711549 Hepacivirus C Species 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000004956 cyclohexylene group Chemical group 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000010710 hepatitis C virus infection Diseases 0.000 claims description 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 2
- 125000004437 phosphorous atom Chemical group 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 29
- 125000001072 heteroaryl group Chemical group 0.000 description 29
- 125000003342 alkenyl group Chemical group 0.000 description 19
- 125000000304 alkynyl group Chemical group 0.000 description 19
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 19
- 125000004429 atom Chemical group 0.000 description 11
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 10
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 10
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 10
- 0 CC(C)(C)C#Cc1cc(N([C@](CC2)CC[C@@]2O*(C)(C)O)C([C@@]2CC=C(C)CC2)=O)c(C(O)=O)[s]1 Chemical compound CC(C)(C)C#Cc1cc(N([C@](CC2)CC[C@@]2O*(C)(C)O)C([C@@]2CC=C(C)CC2)=O)c(C(O)=O)[s]1 0.000 description 6
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 description 5
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 125000005133 alkynyloxy group Chemical group 0.000 description 5
- 125000004104 aryloxy group Chemical group 0.000 description 5
- 125000000000 cycloalkoxy group Chemical group 0.000 description 5
- 150000002367 halogens Chemical class 0.000 description 5
- 125000005553 heteroaryloxy group Chemical group 0.000 description 5
- 125000005844 heterocyclyloxy group Chemical group 0.000 description 5
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 125000004641 (C1-C12) haloalkyl group Chemical group 0.000 description 2
- HPXRVTGHNJAIIH-UHFFFAOYSA-N OC1CCCCC1 Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24087409P | 2009-09-09 | 2009-09-09 | |
| US61/240,874 | 2009-09-09 | ||
| PCT/US2010/047983 WO2011031669A1 (en) | 2009-09-09 | 2010-09-07 | Inhibitors of flaviviridae viruses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013504576A JP2013504576A (ja) | 2013-02-07 |
| JP2013504576A5 true JP2013504576A5 (enExample) | 2013-10-10 |
| JP5774008B2 JP5774008B2 (ja) | 2015-09-02 |
Family
ID=43028061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012528855A Expired - Fee Related JP5774008B2 (ja) | 2009-09-09 | 2010-09-07 | Ｆｌａｖｉｖｉｒｉｄａｅウイルスの阻害剤 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8501714B2 (enExample) |
| EP (1) | EP2507249B1 (enExample) |
| JP (1) | JP5774008B2 (enExample) |
| KR (1) | KR20120081123A (enExample) |
| CN (1) | CN102498118A (enExample) |
| AU (1) | AU2010292411B2 (enExample) |
| BR (1) | BR112012005438A2 (enExample) |
| CA (1) | CA2771124C (enExample) |
| ES (1) | ES2559437T3 (enExample) |
| IN (1) | IN2012DN01855A (enExample) |
| MX (1) | MX2012002925A (enExample) |
| NZ (1) | NZ598208A (enExample) |
| PT (1) | PT2507249E (enExample) |
| WO (1) | WO2011031669A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101330547A (zh) * | 2007-06-20 | 2008-12-24 | 朗迅科技公司 | 在VoIP网络中分布的用于提供服务的媒体资源 |
| KR20120051022A (ko) | 2009-07-21 | 2012-05-21 | 길리애드 사이언시즈, 인코포레이티드 | 플라비비리데 바이러스의억제제 |
| CA2771124C (en) * | 2009-09-09 | 2019-01-15 | Gilead Sciences, Inc. | Inhibitors of flaviviridae viruses |
| EA201290575A1 (ru) | 2010-01-15 | 2013-01-30 | Джилид Сайэнс, Инк. | Ингибиторы вирусов flaviviridae |
| TWI491609B (zh) * | 2010-01-15 | 2015-07-11 | Gilead Sciences Inc | 黃熱病毒科（Ｆｌａｖｉｖｉｒｉｄａｅ）病毒之抑制劑類 |
| JP2013531011A (ja) * | 2010-06-28 | 2013-08-01 | バーテックス ファーマシューティカルズ インコーポレイテッド | フラビウイルス感染の処置または予防のための化合物および方法 |
| EA201300160A1 (ru) * | 2010-07-22 | 2013-06-28 | Новартис Аг | 2,3,5-тризамещенные тиофены и их применение |
| US20130203706A1 (en) * | 2011-06-28 | 2013-08-08 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of flavivirus infections |
| US8741946B2 (en) | 2011-07-13 | 2014-06-03 | Gilead Sciences, Inc. | Inhibitors of flaviviridae viruses |
| GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
| US8927741B2 (en) | 2012-08-17 | 2015-01-06 | Gilead Sciences, Inc. | Synthesis of an antiviral compound |
| US8841340B2 (en) | 2012-08-17 | 2014-09-23 | Gilead Sciences, Inc. | Solid forms of an antiviral compound |
| US8759544B2 (en) * | 2012-08-17 | 2014-06-24 | Gilead Sciences, Inc. | Synthesis of an antiviral compound |
| WO2016106050A1 (en) | 2014-12-26 | 2016-06-30 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| FR3046793B1 (fr) * | 2016-01-14 | 2018-01-05 | Les Laboratoires Servier | Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| CN121974842A (zh) | 2016-05-10 | 2026-05-05 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| EP4717317A3 (en) | 2017-06-20 | 2026-06-03 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| RU2020116571A (ru) | 2017-12-07 | 2021-11-22 | Эмори Юниверсити | N4-гидроксицитидин и производные и связанные с этим противовирусные применения |
| PH12022551160A1 (en) | 2019-11-15 | 2023-09-25 | Janssen Pharmaceuticals Inc | Treatment and prevention of dengue disease |
| CN117731658A (zh) * | 2023-12-05 | 2024-03-22 | 北京凯因格领生物技术有限公司 | 一种乙脑病毒抑制剂 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5861421A (en) | 1995-12-21 | 1999-01-19 | Smithkline Beecham Corporation | 4,4-(disubstituted) cyclohexan-1-one monomers and related compounds |
| US20050119332A1 (en) | 1998-03-12 | 2005-06-02 | Lone Jeppesen | Substituted thiophene compounds as modulators of protein tyrosine phosphatases (PTPases) |
| US20020002199A1 (en) | 1998-03-12 | 2002-01-03 | Lone Jeppesen | Modulators of protein tyrosine phosphatases (ptpases) |
| EP2363396A1 (en) * | 2001-06-11 | 2011-09-07 | Virochem Pharma Inc. | Thiophene derivatives as antiviral agents for flavivirus infection |
| EP1395571A1 (en) | 2001-06-11 | 2004-03-10 | Shire Biochem Inc. | Compounds and methods for the treatment or prevention of flavivirus infections |
| ATE466856T1 (de) * | 2002-12-10 | 2010-05-15 | Virochem Pharma Inc | Verbindungen und methoden zum behandeln oder vorbeugen von flavivirus infektionen |
| DE60332482D1 (de) | 2002-12-10 | 2010-06-17 | Virochem Pharma Inc | Verbindungen und methoden zum behandeln oder vorbeugen von flavivirus infektionen |
| DE10359791A1 (de) | 2003-12-19 | 2005-07-21 | Bayer Healthcare Ag | Substituierte Thiophene |
| WO2005081954A2 (en) | 2004-02-25 | 2005-09-09 | Wyeth | Inhibitors of protein tyrosine phosphatase 1b |
| WO2005095386A1 (en) | 2004-03-30 | 2005-10-13 | Chiron Corporation | Substituted thiophene derivatives as anti-cancer agents |
| DE102004061746A1 (de) | 2004-12-22 | 2006-07-06 | Bayer Healthcare Ag | Alkinyl-substituierte Thiophene |
| DE102005028077A1 (de) | 2004-12-22 | 2006-07-13 | Aicuris Gmbh & Co. Kg | Alkinyl-substituierte Thiophene |
| JP5030947B2 (ja) | 2005-05-13 | 2012-09-19 | ヴァイロケム・ファーマ・インコーポレーテッド | フラビウイルス感染の治療及び予防のための化合物及び方法 |
| AU2007214710A1 (en) | 2006-02-15 | 2007-08-23 | Sanofi-Aventis | Novel amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments |
| SG176488A1 (en) * | 2006-11-15 | 2011-12-29 | Virochem Pharma Inc | Thiophene analogues for the treatment or prevention of flavivirus infections |
| ATE524465T1 (de) | 2006-11-17 | 2011-09-15 | Glaxosmithkline Llc | 2-carboxy-thiophen-derivate als viruzide |
| WO2010065668A1 (en) | 2008-12-03 | 2010-06-10 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| KR20120051022A (ko) | 2009-07-21 | 2012-05-21 | 길리애드 사이언시즈, 인코포레이티드 | 플라비비리데 바이러스의억제제 |
| CA2771124C (en) * | 2009-09-09 | 2019-01-15 | Gilead Sciences, Inc. | Inhibitors of flaviviridae viruses |
| EP2504329A1 (en) | 2009-11-25 | 2012-10-03 | Vertex Pharmaceuticals Incorporated | 5-alkynyl-thiophene-2-carboxylic acid derivatives and their use for the treatment or prevention of flavivirus infections |
| TWI491609B (zh) | 2010-01-15 | 2015-07-11 | Gilead Sciences Inc | 黃熱病毒科（Ｆｌａｖｉｖｉｒｉｄａｅ）病毒之抑制劑類 |
| EA201290575A1 (ru) | 2010-01-15 | 2013-01-30 | Джилид Сайэнс, Инк. | Ингибиторы вирусов flaviviridae |
| JP2013529684A (ja) | 2010-06-28 | 2013-07-22 | バーテックス ファーマシューティカルズ インコーポレイテッド | フラビウイルス感染の処置または予防のための化合物および方法 |
| US8741946B2 (en) | 2011-07-13 | 2014-06-03 | Gilead Sciences, Inc. | Inhibitors of flaviviridae viruses |
-
2010
- 2010-09-07 CA CA2771124A patent/CA2771124C/en not_active Expired - Fee Related
- 2010-09-07 PT PT107639023T patent/PT2507249E/pt unknown
- 2010-09-07 KR KR1020127008996A patent/KR20120081123A/ko not_active Withdrawn
- 2010-09-07 ES ES10763902.3T patent/ES2559437T3/es active Active
- 2010-09-07 US US13/392,467 patent/US8501714B2/en active Active
- 2010-09-07 BR BR112012005438A patent/BR112012005438A2/pt not_active IP Right Cessation
- 2010-09-07 MX MX2012002925A patent/MX2012002925A/es active IP Right Grant
- 2010-09-07 EP EP10763902.3A patent/EP2507249B1/en active Active
- 2010-09-07 IN IN1855DEN2012 patent/IN2012DN01855A/en unknown
- 2010-09-07 JP JP2012528855A patent/JP5774008B2/ja not_active Expired - Fee Related
- 2010-09-07 AU AU2010292411A patent/AU2010292411B2/en not_active Ceased
- 2010-09-07 WO PCT/US2010/047983 patent/WO2011031669A1/en not_active Ceased
- 2010-09-07 CN CN2010800404113A patent/CN102498118A/zh active Pending
- 2010-09-07 NZ NZ598208A patent/NZ598208A/en not_active IP Right Cessation
-
2013
- 2013-06-26 US US13/927,355 patent/US8765722B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013538230A5 (enExample) | ||
| CA3235937A1 (en) | Therapeutic compounds for hiv virus infection | |
| JP5872539B2 (ja) | プリンヌクレオシドホスホルアミダート | |
| JP2012533630A5 (enExample) | ||
| ME01882B (me) | 1 '-supstituisani-karba-nukleozidni prolekovi za antivirusni tretman | |
| JP2014503516A5 (enExample) | ||
| ME02656B (me) | 2' -fluoro supstituisani karba-nukleozidni analozi za antiviralno lečenje | |
| KR20120138242A (ko) | 뉴클레오사이드 포스포르아미데이트 | |
| JP2013517286A5 (enExample) | ||
| IL217228A (en) | Compounds of Type 2'-Deoxy-2'-Fluoro-2'-c-Methyluridine Nucleoside Phosphoramide Compounds | |
| CA2632626A1 (en) | Ester prodrugs of 2'-fluoro-2'-alkyl-2'-deoxycytidines and their use in the treatment of hcv infection | |
| JP2010514768A5 (enExample) | ||
| JP2013544286A5 (enExample) | ||
| JP2010501584A5 (enExample) | ||
| JP2007534636A5 (enExample) | ||
| JP2015063538A (ja) | ヌクレオシドホスホナートが投与された被験者における腎毒性を減少させる方法 | |
| RU2011127079A (ru) | Комбинация производного циклоспорина и нуклеозидов для лечения инфекции вирусом гепатита с | |
| JP2012519691A5 (enExample) | ||
| JP2014532716A5 (enExample) | ||
| ES2488821T3 (es) | Proceso de preparación de un compuesto antiviral | |
| KR20200108903A (ko) | 세포내 감염의 치료 방법 | |
| CN104774194A (zh) | 氘代的丙型肝炎病毒抑制剂 | |
| JP2011529085A5 (enExample) | ||
| ES2237189T3 (es) | Terapia de combinacion para tratar virus de la hepatitis b. | |
| AU2020202894B2 (en) | Methods of preparing tecovirimat |